FDA Inspection 1180586 — NABRIVA THERAPEUTICS US INC
The FDA completed an inspection of NABRIVA THERAPEUTICS US INC on Sep 2, 2022 in Fort Washington, PA. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI)
- End Date
- Sep 2, 2022
- Fiscal Year
- 2022
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Fort Washington, PA (United States)
Additional Details
Postmarket Adverse Drug Experience (PADE)